Adverum Total Revenue vs Operating Income Analysis

ADVM Stock

USD 6.64 0.19 2.95%

Adverum Biotechnologies financial indicator trend analysis is way more than just evaluating Adverum Biotechnologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adverum Biotechnologies is a good investment. Please check the relationship between Adverum Biotechnologies Total Revenue and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

Total Revenue vs Operating Income

Total Revenue vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adverum Biotechnologies Total Revenue account and Operating Income. At this time, the significance of the direction appears to have pay attention.

The correlation between Adverum Biotechnologies' Total Revenue and Operating Income is -0.77. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Operating Income in the same time period over historical financial statements of Adverum Biotechnologies, assuming nothing else is changed. The correlation between historical values of Adverum Biotechnologies' Total Revenue and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Adverum Biotechnologies are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Total Revenue i.e., Adverum Biotechnologies' Total Revenue and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.77

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Total Revenue

Total revenue comprises all receipts Adverum Biotechnologies generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from Adverum Biotechnologies operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Adverum Biotechnologies is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Adverum Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adverum Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.As of the 29th of November 2024, Sales General And Administrative To Revenue is likely to grow to 17.94, while Selling General Administrative is likely to drop about 31.8 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	153.6M	157.1M	127.6M	82.0M
Cost Of Revenue	4.6M	6.5M	5.6M	5.4M

Total Operating Expenses Cost Of Revenue

Adverum Biotechnologies fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Non Currrent Assets Other	Other Assets	Net Tangible Assets
Total Assets		0.57	0.72	0.74	0.94	0.18	0.65	-0.06	-0.61	0.56	0.35	0.66	-0.52	0.94	0.46	-0.19	0.6	0.75	0.82	0.65	0.61	0.94	0.31	0.11	0.43	0.84
Short Long Term Debt Total	0.57		0.55	0.87	0.3	-0.33	0.98	0.58	-0.85	0.41	-0.2	0.98	-0.32	0.29	0.49	-0.57	0.98	0.59	0.82	0.99	0.98	0.31	0.75	0.64	0.87	0.36
Other Current Liab	0.72	0.55		0.5	0.65	-0.29	0.63	0.28	-0.49	0.32	-0.07	0.62	-0.24	0.63	0.68	-0.09	0.56	0.58	0.65	0.58	0.59	0.64	0.16	-0.04	0.44	0.71
Total Current Liabilities	0.74	0.87	0.5		0.55	-0.12	0.88	0.3	-0.89	0.72	0.06	0.89	-0.43	0.55	0.22	-0.41	0.84	0.82	0.95	0.91	0.84	0.56	0.72	0.55	0.76	0.47
Total Stockholder Equity	0.94	0.3	0.65	0.55		0.32	0.42	-0.27	-0.33	0.48	0.46	0.42	-0.47	1.0	0.4	-0.03	0.31	0.65	0.66	0.42	0.33	1.0	-0.01	-0.19	0.11	0.82
Other Liab	0.18	-0.33	-0.29	-0.12	0.32		-0.31	-0.76	0.23	-0.13	0.74	-0.28	-0.23	0.35	0.04	0.45	-0.25	-0.21	-0.1	-0.21	-0.3	0.34	-0.28	-0.15	-0.32	-0.03
Property Plant And Equipment Net	0.65	0.98	0.63	0.88	0.42	-0.31		0.55	-0.8	0.47	-0.18	1.0	-0.34	0.41	0.54	-0.58	0.95	0.65	0.84	0.99	0.96	0.42	0.64	0.51	0.79	0.43
Net Debt	-0.06	0.58	0.28	0.3	-0.27	-0.76	0.55		-0.4	0.15	-0.91	0.54	0.31	-0.3	0.21	-0.58	0.53	0.24	0.25	0.48	0.56	-0.28	0.41	0.33	0.49	0.03
Retained Earnings	-0.61	-0.85	-0.49	-0.89	-0.33	0.23	-0.8	-0.4		-0.57	0.03	-0.81	0.34	-0.34	-0.2	0.36	-0.88	-0.7	-0.89	-0.84	-0.88	-0.36	-0.91	-0.73	-0.94	-0.46
Accounts Payable	0.56	0.41	0.32	0.72	0.48	-0.13	0.47	0.15	-0.57		0.03	0.47	-0.32	0.48	-0.08	-0.28	0.38	0.92	0.65	0.47	0.36	0.49	0.37	0.11	0.34	0.36
Cash	0.35	-0.2	-0.07	0.06	0.46	0.74	-0.18	-0.91	0.03	0.03		-0.17	-0.53	0.49	-0.03	0.42	-0.14	0.0	0.1	-0.1	-0.17	0.48	-0.08	-0.04	-0.12	0.15
Non Current Assets Total	0.66	0.98	0.62	0.89	0.42	-0.28	1.0	0.54	-0.81	0.47	-0.17		-0.34	0.41	0.54	-0.56	0.96	0.65	0.85	0.99	0.96	0.43	0.65	0.52	0.79	0.43
Long Term Debt	-0.52	-0.32	-0.24	-0.43	-0.47	-0.23	-0.34	0.31	0.34	-0.32	-0.53	-0.34		-0.48	-0.2	0.23	-0.34	-0.38	-0.4	-0.37	-0.32	-0.48	-0.27	-0.23	-0.31	-0.35
Cash And Short Term Investments	0.94	0.29	0.63	0.55	1.0	0.35	0.41	-0.3	-0.34	0.48	0.49	0.41	-0.48		0.38	-0.01	0.31	0.64	0.66	0.41	0.33	1.0	0.01	-0.17	0.12	0.82
Net Receivables	0.46	0.49	0.68	0.22	0.4	0.04	0.54	0.21	-0.2	-0.08	-0.03	0.54	-0.2	0.38		-0.19	0.52	0.18	0.33	0.51	0.5	0.39	-0.05	-0.12	0.27	0.37
Common Stock Shares Outstanding	-0.19	-0.57	-0.09	-0.41	-0.03	0.45	-0.58	-0.58	0.36	-0.28	0.42	-0.56	0.23	-0.01	-0.19		-0.53	-0.4	-0.3	-0.52	-0.53	-0.02	-0.43	-0.31	-0.41	-0.25
Non Current Liabilities Total	0.6	0.98	0.56	0.84	0.31	-0.25	0.95	0.53	-0.88	0.38	-0.14	0.96	-0.34	0.31	0.52	-0.53		0.56	0.8	0.96	0.99	0.32	0.78	0.67	0.91	0.39
Other Current Assets	0.75	0.59	0.58	0.82	0.65	-0.21	0.65	0.24	-0.7	0.92	0.0	0.65	-0.38	0.64	0.18	-0.4	0.56		0.83	0.64	0.56	0.66	0.44	0.13	0.49	0.63
Other Stockholder Equity	0.82	0.82	0.65	0.95	0.66	-0.1	0.84	0.25	-0.89	0.65	0.1	0.85	-0.4	0.66	0.33	-0.3	0.8	0.83		0.87	0.81	0.67	0.66	0.43	0.73	0.65
Total Liab	0.65	0.99	0.58	0.91	0.42	-0.21	0.99	0.48	-0.84	0.47	-0.1	0.99	-0.37	0.41	0.51	-0.52	0.96	0.64	0.87		0.96	0.43	0.69	0.58	0.82	0.4
Property Plant And Equipment Gross	0.61	0.98	0.59	0.84	0.33	-0.3	0.96	0.56	-0.88	0.36	-0.17	0.96	-0.32	0.33	0.5	-0.53	0.99	0.56	0.81	0.96		0.34	0.78	0.67	0.9	0.43
Total Current Assets	0.94	0.31	0.64	0.56	1.0	0.34	0.42	-0.28	-0.36	0.49	0.48	0.43	-0.48	1.0	0.39	-0.02	0.32	0.66	0.67	0.43	0.34		0.03	-0.16	0.13	0.82
Property Plant Equipment	0.31	0.75	0.16	0.72	-0.01	-0.28	0.64	0.41	-0.91	0.37	-0.08	0.65	-0.27	0.01	-0.05	-0.43	0.78	0.44	0.66	0.69	0.78	0.03		0.92	0.94	0.2
Non Currrent Assets Other	0.11	0.64	-0.04	0.55	-0.19	-0.15	0.51	0.33	-0.73	0.11	-0.04	0.52	-0.23	-0.17	-0.12	-0.31	0.67	0.13	0.43	0.58	0.67	-0.16	0.92		0.84	-0.06
Other Assets	0.43	0.87	0.44	0.76	0.11	-0.32	0.79	0.49	-0.94	0.34	-0.12	0.79	-0.31	0.12	0.27	-0.41	0.91	0.49	0.73	0.82	0.9	0.13	0.94	0.84		0.29
Net Tangible Assets	0.84	0.36	0.71	0.47	0.82	-0.03	0.43	0.03	-0.46	0.36	0.15	0.43	-0.35	0.82	0.37	-0.25	0.39	0.63	0.65	0.4	0.43	0.82	0.2	-0.06	0.29

Click cells to compare fundamentals

Adverum Biotechnologies Account Relationship Matchups

Adverum Biotechnologies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	222.7M	482.6M	439.7M	308.4M	173.0M	247.9M
Short Long Term Debt Total	32.2M	30.7M	103.0M	106.8M	75.0M	48.0M
Other Current Liab	2.6M	9.1M	14.8M	3.3M	2.1M	3.9M
Total Current Liabilities	19.4M	20.9M	21.3M	32.2M	24.9M	15.0M
Total Stockholder Equity	175.0M	434.3M	316.2M	181.5M	83.5M	79.3M
Other Liab	1.4M	48K	1.1M	1.0M	942.3K	895.2K
Property Plant And Equipment Net	45.8M	47.1M	119.1M	113.9M	67.0M	37.4M
Net Debt	(33.6M)	(31.7M)	68.8M	38.4M	36K	37.8K
Retained Earnings	(385.0M)	(502.5M)	(648.1M)	(802.6M)	(919.8M)	(873.8M)
Accounts Payable	4.1M	2.8M	1.4M	2.2M	1.9M	1.9M
Cash	65.9M	62.4M	34.2M	68.4M	75M	78.2M
Non Current Assets Total	46.9M	48.1M	122.6M	117.8M	70.2M	39.7M
Cash And Short Term Investments	166.0M	429.7M	305.2M	185.6M	96.5M	91.7M
Common Stock Shares Outstanding	6.4M	8.5M	9.8M	9.9M	10.1M	18.4M
Liabilities And Stockholders Equity	222.7M	482.6M	439.7M	308.4M	173.0M	247.9M
Non Current Liabilities Total	28.4M	27.3M	102.2M	94.6M	64.6M	67.9M
Other Current Assets	9.8M	9.4M	6.2M	5.0M	6.2M	4.4M
Other Stockholder Equity	560.7M	937.1M	965.0M	985.7M	1.0B	567.3M
Total Liab	47.8M	48.2M	123.5M	126.9M	89.5M	46.9M
Property Plant And Equipment Gross	24.9M	47.1M	132.2M	130.9M	81.5M	85.6M
Total Current Assets	175.9M	434.4M	317.1M	190.6M	102.8M	97.6M
Accumulated Other Comprehensive Income	(725K)	(261K)	(714K)	(1.5M)	(473K)	(496.7K)
Property Plant Equipment	24.9M	27.7M	33.1M	113.9M	130.9M	137.5M
Non Currrent Assets Other	11K	29K	250K	1.4M	1.2M	1.3M
Other Assets	1.0M	1.0M	3.5M	3.9M	4.5M	4.7M
Net Tangible Assets	175.0M	434.3M	316.2M	181.5M	208.7M	256.7M
Current Deferred Revenue	8.6M	12.3M	16.0M	(6.1M)	(7.0M)	(6.7M)
Common Stock Total Equity	5K	6K	7K	10K	11.5K	6.5K
Retained Earnings Total Equity	(320.5M)	(385.0M)	(502.5M)	(648.1M)	(583.3M)	(554.1M)
Short Term Investments	100.1M	367.3M	271.0M	117.2M	21.5M	20.4M
Capital Surpluse	522.5M	560.7M	937.1M	965.0M	1.1B	599.6M
Short Term Debt	4.0M	8.9M	3.8M	26.5M	20.8M	21.9M
Common Stock	5K	6K	7K	10K	11.5K	7.4K
Non Current Liabilities Other	28.4M	27.3M	102.2M	1.0M	1.2M	1.1M
Net Invested Capital	175.0M	434.3M	316.2M	181.5M	83.5M	79.3M
Net Working Capital	156.5M	413.6M	295.8M	158.3M	77.9M	74.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:

How To Invest In Adverum

Details

Is Adverum Stock a good investment?

Details

What is Adverum Biotechnologies' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.95)

Revenue Per Share

0.059

Quarterly Revenue Growth

(0.70)

Return On Assets

(0.30)

Return On Equity

(0.76)

The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adverum Total Revenue vs Operating Income Analysis

Total Revenue vs Operating Income

Total Revenue vs Operating Income Correlation Analysis

Correlation Coefficient

Total Revenue

Operating Income

Adverum Biotechnologies fundamental ratios Correlations

Adverum Biotechnologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adverum Biotechnologies fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Property Plant And Equipment Net

Other Assets	- 0.94	Retained Earnings
Property Plant Equipment	- 0.91	Retained Earnings
Cash	- 0.91	Net Debt
Other Stockholder Equity	- 0.89	Retained Earnings
Retained Earnings	- 0.89	Total Current Liabilities
Property Plant And Equipment Gross	- 0.88	Retained Earnings